纳米载体设计用于在静脉静脉复原的双重向治疗
Ivan S Alferiev1, Kehan Zhang1, Zoë Folchman-Wagner1
1Division of Cardiology, The Children's Hospital of Philadelphia, and Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Pharmaceutics
|February 24, 2024
概括
这项研究引入了双向磁化纳米粒子 (MNP) 用于治疗血管塑性手术后的动脉复缩. 这种新的方法有效地准并将药物载入的MNP保留在受伤部位,显著抑制动物模型中的缩.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 心血管研究研究心血管研究
背景情况:
- 血管造形术后的动脉再封闭 (静脉炎) 是一个重大的临床挑战.
- 目前治疗复原症的疗法在疗效和特定部位的治疗方面存在局限性.
- 开发有针对性的输送系统对于改善复原症治疗结果至关重要.
研究的目的:
- 研究一种双重向的策略,用于使用药物载入磁化纳米粒子 (MNP) 治疗静脉支架静止症.
- 为了评估MNP的有效性功能化与纤维素-敏捷增强动脉结合和保留.
- 在鼠 carotid stenting模型中评估包利塔塞尔加载MNP的抗性作用.
主要方法:
- 含有帕克利塔克塞尔的可生物降解的MNP被合成和表征.
- 用纤维素激烈来表面修改MNP,以增强动脉壁亲和力.
- 在体外研究中评估了MNP对光滑肌肉细胞的抗增殖作用.
- 在老鼠体内研究评估了使用成像和组织学分析的MNP向,保留和抗性疗效.
主要成果:
- 在不影响磁性特性或抗增殖功能的情况下,MNP得到了高效的功能化.
- 双重向的MNP表现出增强的局部化和在支架动脉中保持长达7天的时间.
- 磁导是动脉定位的主要因素.
- 双重向治疗显著降低了新密度与介质的比率,并在老鼠复缩模型中减少了%的狭窄.
结论:
- 使用纤维素敏捷MNP的抗缩剂的双重向输送提供了一个有前途的新平台来治疗静脉静缩.
- 这种方法可以有效地定位特定地点和治疗剂的持续存在.
- 这些发现支持了使用这种新型纳米粒子系统安全有效地治疗缩的可能性.
关键词:
关联性向的目标是亲缘关系.纤维素纤维素是一种纤维素.磁导指导是指导的磁性指导.磁性纳米粒子是一种磁性纳米粒子.帕克利塔克塞尔 (paclitaxel) 的使用情况静止性静止症是一种静止症.支架是一种支架.更多相关视频
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
513
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
513